Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Company and personnel

25 January 2018

GenSight Biologics reports €55 million 2017 year-end cash position and provides corporate update

25 January 2018

GenSight Biologics Appoints Julio Benedicto as Vice President of Marketing

06 November 2017

GenSight Biologics to Participate in Multiple Conferences in November

26 October 2017

GenSight Biologics Reports its Cash Position as of September 30, 2017

25 October 2017

GenSight Biologics Appoints Barrett Katz as Chief Medical Officer

04 October 2017

GenSight Biologics to Attend Chardan Gene Therapy Conference

02 October 2017

GenSight Biologics integrates the Enternext® PEA-PME 150 index

19 September 2017

GenSight Biologics integrates the CAC® Small, CAC® Mid and Small and CAC® All-Tradable Euronext indexes

28 July 2017

GenSight Biologics Reports Interim Financial Results for the First Half of 2017

23 June 2017

Publication of the securities note having obtained visa no. 17-297 of the AMF in connection with the capital increase of GenSight Biologics

  • View previous 9 articles
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page